pirinixic acid has been researched along with Fatty Liver in 11 studies
pirinixic acid: structure
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study evaluated the effects of gut microbiota modulation by a purified PPAR-alpha agonist (WY14643), a DPP-4 inhibitor (linagliptin), or their association on intestinal barrier integrity, endotoxemia, and hepatic energy metabolism in high-fructose-fed C57BL/6 mice." | 3.96 | Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin. ( Daleprane, JB; Mandarim-de-Lacerda, CA; Martins, FF; Miranda, CS; Silva-Veiga, FM; Souza-Mello, V, 2020) |
| "We have proposed that steatohepatitis results from reactive oxygen species (ROS) acting on accumulated fatty acids to form proinflammatory lipoperoxides." | 1.32 | Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. ( Farrell, GC; Hall, P; Ip, E; Kirsch, R; Leclercq, I; Robertson, G, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Silva-Veiga, FM | 1 |
| Miranda, CS | 1 |
| Martins, FF | 1 |
| Daleprane, JB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Souza-Mello, V | 1 |
| Lebrun, V | 1 |
| Molendi-Coste, O | 1 |
| Lanthier, N | 1 |
| Sempoux, C | 1 |
| Cani, PD | 1 |
| van Rooijen, N | 1 |
| Stärkel, P | 1 |
| Horsmans, Y | 1 |
| Leclercq, IA | 1 |
| Qin, S | 1 |
| Yin, J | 1 |
| Huang, K | 1 |
| Wada, S | 1 |
| Yamazaki, T | 1 |
| Kawano, Y | 1 |
| Miura, S | 1 |
| Ezaki, O | 1 |
| Wierzbicki, M | 1 |
| Chabowski, A | 1 |
| Zendzian-Piotrowska, M | 1 |
| Harasim, E | 1 |
| Górski, J | 1 |
| Teoh, NC | 1 |
| Williams, J | 1 |
| Hartley, J | 1 |
| Yu, J | 1 |
| McCuskey, RS | 1 |
| Farrell, GC | 3 |
| Larter, CZ | 1 |
| Yeh, MM | 1 |
| Van Rooyen, DM | 1 |
| Brooling, J | 1 |
| Ghatora, K | 1 |
| Walter, R | 1 |
| Wanninger, J | 1 |
| Bauer, S | 1 |
| Eisinger, K | 1 |
| Neumeier, M | 1 |
| Weiss, TS | 1 |
| Amann, T | 1 |
| Hellerbrand, C | 1 |
| Schäffler, A | 1 |
| Schölmerich, J | 1 |
| Buechler, C | 1 |
| Ye, JM | 1 |
| Iglesias, MA | 1 |
| Watson, DG | 1 |
| Ellis, B | 1 |
| Wood, L | 1 |
| Jensen, PB | 1 |
| Sørensen, RV | 1 |
| Larsen, PJ | 1 |
| Cooney, GJ | 1 |
| Wassermann, K | 1 |
| Kraegen, EW | 1 |
| Ip, E | 2 |
| Robertson, G | 2 |
| Hall, P | 2 |
| Kirsch, R | 1 |
| Leclercq, I | 2 |
| Farrell, G | 1 |
11 other studies available for pirinixic acid and Fatty Liver
| Article | Year |
|---|---|
Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin.
Topics: Animals; Blood Glucose; Diet; Dipeptidyl-Peptidase IV Inhibitors; Endotoxemia; Fatty Liver; Fructose | 2020 |
Impact of PPAR-α induction on glucose homoeostasis in alcohol-fed mice.
Topics: Alcohol Drinking; Animals; Blood Glucose; Clodronic Acid; Fatty Liver; Female; Glucose; Homeostasis; | 2013 |
Free Fatty Acids Increase Intracellular Lipid Accumulation and Oxidative Stress by Modulating PPARα and SREBP-1c in L-02 Cells.
Topics: Cell Line; Cell Survival; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Hepat | 2016 |
Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice.
Topics: Animals; Anticholesteremic Agents; Blood Glucose; Dietary Fats, Unsaturated; Dose-Response Relations | 2008 |
Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.
Topics: Animals; Dietary Fats; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Lipid Metabolism; Lipid | 2009 |
Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
Topics: Animals; Fatty Liver; Mice; Peroxisome Proliferators; Pyrimidines; Reperfusion Injury; Time Factors | 2010 |
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Topics: Adipose Tissue; Animals; Blotting, Western; Chemokine CCL2; Diabetes Mellitus; Disease Models, Anima | 2012 |
Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis.
Topics: Adiponectin; Anticholesteremic Agents; Connective Tissue Growth Factor; Down-Regulation; Fatty Liver | 2011 |
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; L | 2003 |
Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice.
Topics: Animal Feed; Animals; Anticholesteremic Agents; Choline Deficiency; Cytochrome P-450 CYP4A; Cytochro | 2003 |
Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Topics: Animals; Cell Adhesion Molecules; Connective Tissue Growth Factor; Dietary Fats; Fatty Liver; Gene E | 2004 |